Follistatin For Sale

Direct Answer: Sourcing High-Purity Follistatin for Laboratory Research

Sourcing research-grade follistatin for sale requires strict adherence to quality verification standards, ensuring that experimental reagents are free from bacterial endotoxins, structural degradation, and synthesis impurities. Follistatin (FST) is an autocrine glycoprotein that functions primarily as a high-affinity antagonist to members of the transforming growth factor-beta (TGF-β) superfamily, most notably activin A and myostatin (growth differentiation factor 8, or GDF-8).

When purchasing compounds for institutional study through the PX1 Research catalog, laboratories must demand complete analytical transparency. PX1 Research provides high-purity Follistatin-315 and related research variants, synthesized in GMP-compliant USA facilities. Every batch includes a lot-specific Certificate of Analysis (COA) incorporating reverse-phase high-performance liquid chromatography (RP-HPLC) and electrospray ionization mass spectrometry (ESI-MS) to confirm molecular weight, chemical purity, and sequence integrity before release for preclinical investigation.

Biochemical Mechanism and Receptor Kinetics of Follistatin

In cell culture and animal models, Follistatin operates through a distinct stoichiometric mechanism. Rather than directly activating membrane-bound receptors, Follistatin acts as a soluble binding protein that neutralizes specific growth factors before they can engage their respective signaling complexes. Preclinical studies indicate that one molecule of Follistatin binds dimerized activin A or myostatin with high affinity, effectively masking the receptor-binding epitopes on the ligand.

By sequestering myostatin and activin, Follistatin prevents these ligands from binding to ActRIIA and ActRIIB (Activin Type II Receptors). Under normal conditions, ligand binding to ActRIIB induces the recruitment and phosphorylation of ALK4 or ALK5 type I receptors, which subsequently triggers downstream intracellular signaling via the Smad2/3 transcriptional cascade. Smad2/3 phosphorylation leads to upregulation of gene expression programs that inhibit protein synthesis and downregulate muscle cell proliferation.

When researchers introduce exogenous Follistatin research compounds into cell-based assays or tissue models, Smad2/3 phosphorylation is dramatically suppressed. This clearance of inhibitory signaling permits increased activity along the Akt/mTOR (mammalian target of rapamycin) axis, promoting net intracellular protein accretion and cellular differentiation in preclinical models. Detailed mechanistic breakdowns of these cascades are documented throughout our TGF-β pathway research library.

Structural Isoforms: Follistatin-315, Follistatin-288, and FST-300

When evaluating follistatin for sale, principal investigators must select the specific structural isoform best suited to their experimental design. The human FST gene produces primary mRNA transcripts that undergo alternative splicing and post-translational processing, resulting in three predominant protein variants: Follistatin-288 (FST-288), Follistatin-315 (FST-315), and Follistatin-300 (FST-300).

FST-288 represents the membrane-bound isoform. It contains an unmasked basic C-terminal domain rich in lysine and arginine residues, conferring high binding affinity for cell-surface heparin sulfate proteoglycans (HSPGs). In vitro assays demonstrate that FST-288 rapidly anchors to extracellular matrices, limiting its diffusion and making it an exceptional tool for studying localized, tissue-specific activin and myostatin inhibition.

FST-315 is the predominant circulating isoform found in systemic plasma. It possesses an extended acidic C-terminal tail that electrostatically blocks the heparin-binding region, preventing immediate attachment to cell-surface HSPGs. Consequently, FST-315 exhibits a longer systemic biological half-life in rodent models, circulating broadly to neutralize target ligands throughout distant physiological compartments. Upon enzymatic cleavage of its C-terminal extension, FST-315 converts to FST-300, an intermediate form with moderate matrix-binding capability. Selecting the correct variant is crucial when designing protocols around growth factor signaling peptides.

Preclinical Literature: Cellular Proliferation, Hypertrophy, and Fibrosis

The scientific literature regarding Follistatin spans decades of cellular biology, endocrinology, and regenerative medicine studies. In rodent models of skeletal muscle wasting, continuous exposure to recombinant Follistatin has been shown to induce marked increases in muscle cross-sectional area without triggering pathological cardiac hypertrophy. In vitro myoblast cultures treated with Follistatin exhibit accelerated fusion into mature, multinucleated myotubes, accompanied by upregulated expression of myogenin and MyoD.

Beyond skeletal tissue models, preclinical investigations have evaluated Follistatin's role in hepatic, renal, and pulmonary fibrotic cascades. Because activin A acts as a potent pro-fibrotic cytokine that stimulates collagen deposition and myofibroblast differentiation, Follistatin-mediated activin neutralization has demonstrated protective anti-fibrotic effects in animal models of hepatic injury and chronic renal insufficiency.

Furthermore, exploratory animal studies have investigated Follistatin in metabolic regulation. By suppressing myostatin and activin signaling in adipose tissue, preclinical administration of Follistatin was observed to enhance brown adipose tissue (BAT) recruitment and improve systemic glucose tolerance in diet-induced obesity models. These biological outcomes underscore the necessity of using highly purified, un-degraded reagents to ensure reproduceable experimental data.

Comparative Class Analysis: Follistatin vs. Allied TGF-β and Growth Regulators

To contextualize Follistatin within the broader landscape of growth-modulating and tissue-repair research compounds, researchers frequently compare its biochemical profile with alternative target-specific peptides. While Follistatin functions through direct ligand sequestration, other research peptides operate through distinct upstream or downstream signaling pathways.

For example, soluble ActRIIB decoy receptors (such as ActRIIB-Fc fusion proteins) act as ligand traps for a broader spectrum of TGF-β family members, including GDF-11 and BMP-9, which can result in off-target vascular effects in preclinical models. Follistatin, by contrast, exhibits a more localized binding affinity concentrated on activin A and myostatin. When compared to indirect muscle growth regulators like IGF-1 LR3, which acts as a potent tyrosine kinase receptor agonist along the MAPK/Akt pathway, Follistatin operates entirely via disinhibition rather than direct receptor stimulation.

Similarly, while tissue regeneration models frequently utilize cytoprotective compounds like BPC-157 or TB-500 to investigate angiogenesis and focal adhesion kinase activity, Follistatin addresses extracellular matrix remodeling primarily through TGF-β cytokine neutralization. A comparative summary of these classes is detailed in the table below.

Analytical Verification Standards: HPLC, MS, and Endotoxin Testing

In modern biochemical research, experimental integrity relies on uncompromising supplier verification. Acquiring follistatin for sale without verified analytical documentation risks introducing truncated peptide fragments, chemical contaminants, or endotoxins into sensitive cell cultures, which can alter cytokine expression and skew experimental data.

PX1 Research mandates strict quality assurance protocols for every lot synthesized in our USA-based facilities. We utilize two primary analytical techniques to verify peptide integrity:

1. Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Establishes chemical purity by separating the target peptide from synthesis byproducts, truncated sequences, and organic impurities. PX1 Research guarantees a minimum purity threshold of 98.0% across all research lots.

2. Electrospray Ionization Mass Spectrometry (ESI-MS): Accurately measures the precise molecular weight of the purified protein, confirming sequence identity and verifying the absence of undesirable post-translational modifications or incorrect disulfide bond linkages.

Additionally, because Follistatin is frequently employed in cell culture and preclinical animal assays, bacterial endotoxin content must be strictly controlled. Endotoxins (lipopolysaccharides derived from Gram-negative bacterial cell walls) trigger acute inflammatory responses via Toll-like receptor 4 (TLR4), confounding cellular study outcomes. PX1 Research subjects every batch to the Chromogenic Limulus Amebocyte Lysate (LAL) assay, ensuring endotoxin levels remain below 0.01 EU/µg. Detailed verification procedures are published in our analytical testing guide.

Laboratory Reconstitution and Handling Protocols

Reconstituting lyophilized proteins like Follistatin requires precise laboratory techniques to avoid denaturing the tertiary protein structure or losing material due to non-specific binding to container walls. Research personnel should adhere to standardized aseptic procedures within a laminar flow hood when preparing stock solutions.

Lyophilized Follistatin should first be brought to room temperature prior to reconstitution to minimize moisture condensation inside the vial. For most in vitro binding assays, the recommended reconstitution diluent is sterile, low-endotoxin Phosphate-Buffered Saline (PBS, pH 7.4) or sterile bacteriostatic water containing 0.9% benzyl alcohol for multi-use laboratory applications.

To minimize non-specific adsorption of the protein to plastic polypropylene tubes or glass walls at low concentrations (<100 µg/mL), investigators often supplement the reconstitution diluent with a carrier protein, such as 0.1% Recombinant Human Serum Albumin (HSA) or Bovine Serum Albumin (BSA). Gentle inversion or mild swirling should be used to dissolve the cake; vigorous vortexing or rapid mechanical agitation must be strictly avoided as shear forces can induce protein aggregation or unfolding.

Storage Conditions and Lyophilized Stability

Proper storage conditions are critical for maintaining the structural bioactivity of lyophilized and reconstituted Follistatin over extended experimental timelines. Lyophilized peptides are inherently more stable than liquid solutions, but exposure to heat, light, or atmospheric humidity will accelerate chemical degradation pathways such as deamidation, oxidation, and aggregation.

Upon receipt from PX1 Research, unopened lyophilized vials should be stored at -20°C for short-to-medium term storage, or at -80°C for long-term storage exceeding six months. Under these ultralow temperature conditions, the dried protein cake maintains structural integrity for up to 24 months.

Once reconstituted into aqueous liquid solutions, stock aliquots should be divided into single-use working volumes using low-binding microcentrifuge tubes. Liquid aliquots stored at 2°C to 8°C are stable for up to 7 days. For long-term liquid storage, aliquots must be frozen immediately at -80°C. Repeated freeze-thaw cycles must be strictly avoided, as the micro-ice crystal formation during re-freezing disrupts hydrogen bonding and destabilizes the tertiary protein structure. Laboratories requiring custom batch volumes or institutional supply agreements can consult our wholesale account team.

Supplier Selection and Institutional Procurement for PX1 Research Compounds

Selecting a reliable supplier for research-grade peptides requires evaluating manufacturing consistency, analytical compliance, and logistics security. Low-quality suppliers often utilize offshore contract manufacturers without verified Quality Management Systems (QMS), resulting in batch-to-batch variability and unverified endotoxin contamination.

PX1 Research operates dedicated manufacturing and distribution hubs in California and Arizona, providing rapid same-day dispatch (Monday through Friday) for institutional orders. Our state-of-the-art facilities comply with Current Good Manufacturing Practice (cGMP) guidelines, and our testing procedures are validated by ISO 17025 accredited analytical laboratories.

Principal investigators, laboratory directors, and procurement officers sourcing follistatin for sale receive fully traceable lot documentation with every order. This level of verification ensures that preclinical studies can be executed with absolute consistency, reproducible metrics, and minimal experimental noise.